Seribantumab

{{Infobox drug | Watchedfields = changed | verifiedrevid = 470603044 | IUPAC_name = (2S)-2-amino-3-(4-{[2-amino-3-(4-hydroxyphenyl)propanoyl]amino}phenyl)propanoic acid | image = | tradename = | Drugs.com = | MedlinePlus = | pregnancy_category = | legal_status = | routes_of_administration = | bioavailability = | protein_bound = | metabolism = | elimination_half-life = | excretion = | CAS_number = | ATC_prefix = | ATC_suffix = | PubChem = | DrugBank = | ChemSpider = | UNII = | KEGG = | ChEMBL = | synonyms = }}

Seribantumab is an experimental monoclonal antibody designed for the treatment of cancer. It specifically targets the ErbB3 receptor, a member of the epidermal growth factor receptor (EGFR) family, which plays a significant role in the pathology of several types of cancer, including breast cancer, lung cancer, and ovarian cancer.

Development and Mechanism

Seribantumab works by inhibiting the activity of the ErbB3 receptor, which is often overexpressed in cancer cells. By blocking this receptor, seribantumab can interfere with the proliferative signaling pathways that promote cancer cell growth and survival.

The development of seribantumab has been part of a broader trend in cancer treatment focusing on targeted therapies, which aim to attack specific molecular targets associated with cancer, while sparing normal cells. This approach can potentially lead to treatments with higher efficacy and fewer side effects compared to traditional chemotherapy.

Clinical Trials

Seribantumab has been evaluated in various clinical trials for its effectiveness and safety in treating different types of cancers. These studies have explored its use as a single agent and in combination with other therapies.

Current Status

As of the last update, seribantumab has not yet received approval from regulatory bodies such as the Food and Drug Administration (FDA) for public use. Research is ongoing, and the future of seribantumab will depend on the outcomes of ongoing and future clinical trials.

See Also

• Monoclonal antibodies in cancer therapy
• Targeted therapy
• Oncology